FR2931362B1 - L'opiorphine pour une utilisation en tant que psychostimulant. - Google Patents

L'opiorphine pour une utilisation en tant que psychostimulant.

Info

Publication number
FR2931362B1
FR2931362B1 FR0853400A FR0853400A FR2931362B1 FR 2931362 B1 FR2931362 B1 FR 2931362B1 FR 0853400 A FR0853400 A FR 0853400A FR 0853400 A FR0853400 A FR 0853400A FR 2931362 B1 FR2931362 B1 FR 2931362B1
Authority
FR
France
Prior art keywords
opiorphine
psychostimulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0853400A
Other languages
English (en)
Other versions
FR2931362A1 (fr
Inventor
Catherine Rougeot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0853400A priority Critical patent/FR2931362B1/fr
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to BRPI0909592A priority patent/BRPI0909592A2/pt
Priority to RU2010153244/15A priority patent/RU2526819C2/ru
Priority to EP20183885.1A priority patent/EP3804744A1/fr
Priority to JP2011510994A priority patent/JP2011521002A/ja
Priority to EP09761603A priority patent/EP2307039A2/fr
Priority to CN2009801281531A priority patent/CN102123725A/zh
Priority to EP23152969.4A priority patent/EP4218786A3/fr
Priority to KR1020107028778A priority patent/KR20110020857A/ko
Priority to EP15188991.2A priority patent/EP3009142A1/fr
Priority to AU2009256765A priority patent/AU2009256765B2/en
Priority to CA2725243A priority patent/CA2725243C/fr
Priority to PCT/EP2009/056390 priority patent/WO2009150040A2/fr
Priority to US12/994,534 priority patent/US20110178021A1/en
Priority to MX2010012856A priority patent/MX2010012856A/es
Publication of FR2931362A1 publication Critical patent/FR2931362A1/fr
Priority to IL209462A priority patent/IL209462A/en
Priority to JP2015018361A priority patent/JP2015131810A/ja
Priority to US14/730,396 priority patent/US20150329608A1/en
Publication of FR2931362B1 publication Critical patent/FR2931362B1/fr
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR0853400A 2008-05-26 2008-05-26 L'opiorphine pour une utilisation en tant que psychostimulant. Active FR2931362B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0853400A FR2931362B1 (fr) 2008-05-26 2008-05-26 L'opiorphine pour une utilisation en tant que psychostimulant.
PCT/EP2009/056390 WO2009150040A2 (fr) 2008-05-26 2009-05-26 Opiorphine destinée à être utilisée en tant qu’agent psychostimulant
RU2010153244/15A RU2526819C2 (ru) 2008-05-26 2009-05-26 Применение опиорфина в качестве психостимулирующего агента
JP2011510994A JP2011521002A (ja) 2008-05-26 2009-05-26 精神刺激剤として使用するためのオピオルフィン
EP09761603A EP2307039A2 (fr) 2008-05-26 2009-05-26 Opiorphine destinée à être utilisée en tant qu' agent psychostimulant
CN2009801281531A CN102123725A (zh) 2008-05-26 2009-05-26 用作精神刺激剂的Opiorphin
EP23152969.4A EP4218786A3 (fr) 2008-05-26 2009-05-26 Opiorphine destinée à être utilisée comme agent analgésique
KR1020107028778A KR20110020857A (ko) 2008-05-26 2009-05-26 정신 자극제로 사용되는 오피오르핀
US12/994,534 US20110178021A1 (en) 2008-05-26 2009-05-26 Opiorphin for use as a psychostimulant agent
AU2009256765A AU2009256765B2 (en) 2008-05-26 2009-05-26 Opiorphin for use as a psychostimulant agent
BRPI0909592A BRPI0909592A2 (pt) 2008-05-26 2009-05-26 "peptídeo para uso como psicoestimulante, peptídeo para a ativação de uma via opioidérgica, método de tratamento ou prevenção de uma doença e uso de um peptídeo"
EP20183885.1A EP3804744A1 (fr) 2008-05-26 2009-05-26 Opiorphine destinée à être utilisée comme agent analgésique
EP15188991.2A EP3009142A1 (fr) 2008-05-26 2009-05-26 Opiorphine destinée à être utilisée comme agent analgésique
MX2010012856A MX2010012856A (es) 2008-05-26 2009-05-26 Opiorfina para el uso como agente psicoestimulante.
CA2725243A CA2725243C (fr) 2008-05-26 2009-05-26 Opiorphine destinee au traitement de la douleur
IL209462A IL209462A (en) 2008-05-26 2010-11-21 Use of peptides containing maturation products of proline-rich basic tear protein in the preparation of drugs to treat a variety of diseases
JP2015018361A JP2015131810A (ja) 2008-05-26 2015-02-02 精神刺激剤として使用するためのオピオルフィン
US14/730,396 US20150329608A1 (en) 2008-05-26 2015-06-04 Opiorphin for use as a psychostimulant agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0853400A FR2931362B1 (fr) 2008-05-26 2008-05-26 L'opiorphine pour une utilisation en tant que psychostimulant.

Publications (2)

Publication Number Publication Date
FR2931362A1 FR2931362A1 (fr) 2009-11-27
FR2931362B1 true FR2931362B1 (fr) 2017-08-18

Family

ID=40301816

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0853400A Active FR2931362B1 (fr) 2008-05-26 2008-05-26 L'opiorphine pour une utilisation en tant que psychostimulant.

Country Status (13)

Country Link
US (2) US20110178021A1 (fr)
EP (4) EP3009142A1 (fr)
JP (2) JP2011521002A (fr)
KR (1) KR20110020857A (fr)
CN (1) CN102123725A (fr)
AU (1) AU2009256765B2 (fr)
BR (1) BRPI0909592A2 (fr)
CA (1) CA2725243C (fr)
FR (1) FR2931362B1 (fr)
IL (1) IL209462A (fr)
MX (1) MX2010012856A (fr)
RU (1) RU2526819C2 (fr)
WO (1) WO2009150040A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1577320T3 (da) 2004-03-19 2012-10-15 Pasteur Institut Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider
JP5788788B2 (ja) 2008-04-07 2015-10-07 アンスティテュ パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ エンケファリンを分解するエクトペプチダーゼを強力に阻害するオピオルフィンペプチド誘導体
US9935633B2 (en) 2015-06-30 2018-04-03 Semiconductor Energy Laboratory Co., Ltd. Logic circuit, semiconductor device, electronic component, and electronic device
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
KR20210038843A (ko) * 2018-05-18 2021-04-08 오비드 테라퓨틱스 인크. 주의력 결핍 과잉 행동 장애를 치료하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
NZ516477A (en) * 1999-06-23 2004-02-27 Pasteur Institut Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
DE60018085T2 (de) * 2000-12-22 2005-07-07 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
DK1577320T3 (da) * 2004-03-19 2012-10-15 Pasteur Institut Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider
WO2009090265A1 (fr) * 2008-01-18 2009-07-23 Institut Pasteur Procédé pour identifier des agonistes ou antagonistes de bplp et de l'opiorphine
JP5788788B2 (ja) * 2008-04-07 2015-10-07 アンスティテュ パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ エンケファリンを分解するエクトペプチダーゼを強力に阻害するオピオルフィンペプチド誘導体

Also Published As

Publication number Publication date
JP2011521002A (ja) 2011-07-21
WO2009150040A3 (fr) 2010-04-15
IL209462A0 (en) 2011-01-31
EP2307039A2 (fr) 2011-04-13
BRPI0909592A2 (pt) 2015-12-01
MX2010012856A (es) 2011-03-15
IL209462A (en) 2017-08-31
RU2526819C2 (ru) 2014-08-27
US20110178021A1 (en) 2011-07-21
EP4218786A3 (fr) 2023-08-16
WO2009150040A2 (fr) 2009-12-17
RU2010153244A (ru) 2012-07-10
CN102123725A (zh) 2011-07-13
EP3804744A1 (fr) 2021-04-14
KR20110020857A (ko) 2011-03-03
AU2009256765A1 (en) 2009-12-17
CA2725243A1 (fr) 2009-12-17
AU2009256765B2 (en) 2015-04-16
JP2015131810A (ja) 2015-07-23
CA2725243C (fr) 2020-03-10
FR2931362A1 (fr) 2009-11-27
EP3009142A1 (fr) 2016-04-20
US20150329608A1 (en) 2015-11-19
EP4218786A2 (fr) 2023-08-02

Similar Documents

Publication Publication Date Title
BRPI0906607A2 (pt) Agentes de coalescência eficazes.
CL2008001011S1 (es) Recipiente.
BRPI0919024A2 (pt) compostos que seletivamente modulam o receptor cb2
FR2923950B1 (fr) Coupleur bidirectionnel integre.
CL2007002246S1 (es) Contenedor.
CL2007003665S1 (es) Envase.
FR2903733B1 (fr) Turbomoteur pour aeronef.
FR2928961B1 (fr) Distributeur sectorise pour une turbomachine.
FR2931362B1 (fr) L'opiorphine pour une utilisation en tant que psychostimulant.
FR2936492B1 (fr) Nacelle pour turboreacteur.
CL2007002131S1 (es) Contenedor.
FR2927628B1 (fr) Composition comprenant un tensioactif pour des bitumes
FR2984753B1 (fr) Bloqueur de pied pour la remontee le long d'une corde
FR2928841B1 (fr) Bloqueur de pied pour la remontee le long d'une corde
CL2008001012S1 (es) Recipiente.
FR2945442B1 (fr) Utilisation de delta-tocopheryl-glucide en tant qu'agent depigmentant.
ITPN20080006A1 (it) "macchina lava-asciuga pavimenti perfezionata".
FR2917668B1 (fr) Indicateur d'usure pour pneumatique
DE112008002325A5 (de) Zusammenklappbarer Ausleger
CL2007002130S1 (es) Dispensador.
NL1035553A1 (nl) Inklapbare manbak.
NL2002599A1 (nl) Hoogwerker.
FR2929174B1 (fr) Pince pour pare-soleil.
FR2898291B3 (fr) Normographe pour le rasage.
FR2926547B1 (fr) 5-°1-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h- cyclopropa°a!naphtalen-4-yl)-3-methylbutyl!-2,4,6-trihydroxy -1,3-benzenedicarboxaldehyde en tant que medicaments.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16